Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to" We", "Us", "Company" or the "Company" refer to Regen BioPharma, Inc.

		Three Months Ended
		June 30, 2026								June 30, 2025								Changes
		Amount				Percent of Revenue				Amount				Percent of Revenue				Amount				Percentage
Net revenue:
Revenues		$	31,640				53.57	%		$	31,640				13.38	%			0				0.00	%
Revenues, Related Party		$	27,425				46.43	%			27,425				11.59	%			0				0.00	%
Net revenue			59,065				100.00	%			59,065				24.97	%			0				0.00	%
Operating expenses:
Research and Development			0				0.00	%			0				0.00	%			0				0.00	%
General and Administrative			13,842				23.44	%			30,697				12.98	%			(16,855	)			-121.76	%
Consulting and Professional Fees			20,694				35.04	%			46,624				19.71	%			(25,930	)			-125.30	%
Rent			0				0.00	%			22,500				9.51	%			(22,500	)			-100.00	%
Total operating expenses			34,536				58.47	%			99,821				42.20	%			(65,285	)			-189.03	%
Loss from operations			24,528				41.53	%			(40,756	)			-17.23	%			65,284				266.16	%
Other income (expense):
Interest Expense			(30,360	)			-51.40	%			-24638				-10.42	%			(5,722	)			18.85	%
Interest Expense attributable to Amortization of Discount			(8,753	)			-14.82	%			-12639				-5.34	%			3,886				-44.39	%
Derivative Income (Expense)			(623,200	)			-1055.11	%			-89259				-37.73	%			(533,941	)			85.68	%
Penalties			0				0.00	%							0.00	%			0				0.00	%
Financing Fees			0												0.00	%			0				-100.00	%
Total other income (expense), net			(662,313	)			-1121.34	%			(126,536	)			-53.49	%			(535,777	)			80.89	%
Net Income (Loss) before income taxes			(637,785	)			-1079.81	%			(167,292	)			-70.72	%			(470,493	)			73.77	%
							0.00	%
Income tax provision			0												0
Net Income (Loss)		$	(637,785	)			-1079.81	%		$	(167,292	)			-70.72	%			(470,493	)			73.77	%

		Nine Months Ended
		June 30, 2026								June 30, 2025								Changes
		Amount				Percent of Revenue				Amount				Percent of Revenue				Amount				Percentage
Net revenue:
Revenues		$	94,920				53.57	%		$	94,920				40.13	%			0				0.00	%
Revenues, Related Party			82,274				46.43	%			82,275				34.78	%			-1				0.00	%
Net revenue			177,194				100.00	%			177,195				74.90	%			-1				0.00	%
Operating expenses:
Research and Development			212,216				119.76	%			0				0.00	%			212,216				100.00	%
General and Administrative			277,871				156.82	%			57,364				24.25	%			220,507				79.36	%
Consulting and Professional Fees			352,912				199.17	%			267,816				113.21	%			85,096				24.11	%
Rent			15,000				8.47	%			67,500				28.53	%			(52,500	)			-350.00	%
Total operating expenses			857,999				484.21	%			392,680				166.00	%			465,319				54.23	%
Loss from operations			(680,805	)			-384.21	%			(215,485	)			-91.09	%			(465,320	)			68.35	%
Other income (expense):
Interest Expense			(84,300	)			-47.58	%			(72,319	)			-30.57	%			(11,981	)			14.21	%
Interest Expense attributable to Amortization of Discount			(26,260	)			-14.82	%			(37,917	)			-16.03	%			11,657				-44.39	%
Derivative Income (Expense)			177,654				100.26	%			(376,312	)			-159.08	%			553,966				311.82	%
Penalties			0				0.00	%			0				0.00	%			0				0.00	%
Financing Fees			0								0				0.00	%			0				-100.00	%
Total other income (expense), net			67,094				37.86	%			(486,548	)			-205.68	%			553,642				825.17	%
Net Income (Loss) before income taxes			(613,711	)			-346.35	%			(702,033	)			-296.77	%			88,322				-14.39	%
							0.00	%
Income tax provision			0								0
Net Income (loss)		$	(613,711	)			-346.35	%		$	(702,033	)			-296.77	%			88,322				-14.39	%

Results of Operations

Three months ended June 30, 2026 and 2025

Revenues

Revenues from continuing operations were $59,065 for the three months ended June 30,2026 and $59,065 for the same period ended 2025. $27,425 of revenue from related parties recognized during the three months ended June 30, 2026 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did $27,425 for the period ended 2025. $31,640 of revenue recognized during both of the three months ended June 30, 2025 and 2026 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating Expenses

Operating Expense were $34,536 for the three months ended June 30, 2026 and $ 99,821 for the same period ended 2025. The primary operating expense for 2026 consists of $ 20,694 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional fees expenditure were $46,624. During the period ended 2026 General and Administrative expenses amounted to $13,842 constituting the second largest expense recognized during that quarter.

Other Income

For the three months ended March 31 2026, the Company reported a net other loss of $662,313 whereas in the same period ended 2025 the Company reported the net other income (loss) of $(126,536). Net other income for the quarter ended 2026 was primarily driven by Derivative Loss of $623,200 recognized during the quarter ended 2026. The Company also recognized higher interest expense and lower amortization expenses as compared to the quarter ended 2025.

Net Income (Loss)

The Company recognized Profit from Operations of $24,528 during the three months ended June 30, 2026 whereas the Company recognized an Operating Loss of $40,756 for the same period ended 2025. The increase in operating loss during the period ended 2025 relative to the period ended 2026 is larger expenses being incurred in all expense categories.

Net Loss is $ 637,785 for the three months ended June 30, 2026 as opposed to a Net Loss of $167,292 for the same period ended 2025. The difference is primarily attributable to the recognition by the Company of greater Derivative Loss during the period ended in 2026.

Nine Months ended June 30, 2026 and 2025

Revenues

Revenues from continuing operations were $177,194 for the Nine Months ended June 30, 2026 which is essentially equivalent to Revenues from continuing operations for the same period ended 2025. $82,274 of revenue from related parties recognized during the Nine Months ended June 30, 2026 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did essentially equivalent revenue from related parties for the period ended 2025. $94,920 of revenue recognized during both of the nine months ended June 30, 2025 and 2026 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating Expenses

Operating Expenses were $857,999 for the Nine Months ended June 30, 2026 and $ 392,680 for the same period ended 2025. The primary operating expense for 2026 consists of $ 352,912 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional fees expenditure were $267,816. During the period ended 2026 General and Administrative expenses amounted to $277,871 constituting the second largest expense recognized during that quarter.

Other Income

For the nine months ended June 30, 2026, the Company reported a net other income of $67,094 whereas in the same period ended 2025 the Company reported the net other expense of $486,548. Net other income for the nine months ended 2026 was primarily driven by Derivative Income of $177,654 recognized during the nine months ended 2026. The Company also recognized higher interest expense and lower amortization expenses as compared to the period ended 2025.

Net Income (Loss)

The Company recognized an Operating Loss of $680,805 during the nine months ended June 30, 2026 whereas the Company recognized an Operating Loss of $215,485 for the same period ended 2025. The increase in operating loss is primarily attributable to an increase in all expense categories other than rent incurred during the period ended 2026 as compared to the period ended in 2025.

Net Loss was $ 613,711 for the nine months ended June 30, 2026 as opposed to a Net Loss of $702,033 for the same period ended 2025. The difference is primarily attributable to the recognition by the Company of Derivative Income during the period ended in 2026.

Working capital deficit decreased by $402,977 from September 30, 2025 to June 30, 2026, primarily due to a decrease in Derivative Liability.

		Nine Months ended June 30
		2026				2025
Net cash used in operating activities		$	(285,244	)		$	(223,586	)
Net cash provided by financing activities			215,927				224,631
Net increase (decrease) in cash and cash equivalents		$	(69,317	)		$	1,045

Liquidity and Capital Resources

Operating Activities

Net cash used in operating activities for the nine months ended June 30, 2026 was $285,244 compared to $223,586, for the same period ended 2025. The increase in cash used in operating activities is primarily attributable to increased operating expenses incurred by the Company during the nine months ended June 30, 2026 as compared to the same period ended 2025.

Financing Activities

Net cash generated by financing activities for the nine months ended June 30, 2026 was $215,927 which consisted of proceeds from sales of newly issued common stock and borrowings from related parties.

Liquidity & Capital Resources Outlook

As of June 30 2026, the Company had cash of $ 239 and net working deficit of approximately $5.9 million.

The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has incurred and expects to continue incur significant research & development cost for products development.

The accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of June 30, 2026, the Company had cash of approximately $239 and an accumulated deficit of approximately $22 million. The Company has incurred recurring losses, experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.

Capital Expenditure Commitments

As of June 30, 2026 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.